Stiglund et al. [52] demonstrated the potential of ST1A1, ADA, Flt3L, EN-RAGE, IL-6, and IL-18 as biomarkers for MASH. This evidence concerns the gene FLT3LG and metabolic dysfunction-associated steatohepatitis.